

Growth Factor Receptors and Liver Injury

ABSTRACT

Aims: The aim of this study is to investigate the expression pattern of transforming growth factor β receptor I (TGF β RI) and fibroblast growth factor receptor 3 (FGFR3) at the different stages of liver injury including acute injury, fibrosis and cirrhosis.

Study design: Controlled experiment

Place and Duration of Study: Department of Biochemistry and Department of Pharmacology and Toxicology, Faculty of Pharmacy (boys) Al-Azhar University, between February 2015 and June 2015.

Methodology: Four Sprague-Dawley rats groups were used for the experiment. **Control group:** 9 rats received corn oil; **acute toxicity group:** 10 rats were injected 50 % CCl₄ in corn oil (4 ml/kg/IP/single dose); **6 weeks group:** 12 rats were injected with 50% CCl₄ in corn oil (4 ml/kg/IP/twice weekly/6 weeks); **11weeks group:** 10 rats were injected with 50 % CCl₄ in corn oil (4 ml/kg/IP/twice weekly/6 weeks) followed by 5 weeks of CCl₄ treatment with the half previous dose.

On the day after the last dose, rats were anesthetized with diethyl ether and blood samples were collected for measurement of blood chemistry. The animals then were euthanized, and tissue samples from the livers were harvested and divided into 2 parts; **the first** was processed for standard histology and immunofluorescence techniques and the other was homogenized for oxidative status assessment.

Results: TGF β RI and FGFR3 were shown to upregulate in chronic liver injury including stages of fibrosis and cirrhosis. While TGF β RI was shown to be located mainly in the cell membrane, the cytoplasm was shown to be the main site for FGFR3 expression.

Conclusion: TGF β RI and FGFR3 were suggested to be of critical importance in pathogenesis of chronic liver injury so they may be used as a target for chronic liver injury therapy and/or candidate marker for diagnosis and/or prognosis of chronic liver injury.

Keywords: TGF β RI, FGFR3, fibrosis, cirrhosis

1. INTRODUCTION

Liver plays a limitless role in the preservation and body homeostasis regulation. It is included in most biochemical pathways to growth, protection against disease, nutrient fund, energy facility and reproduction (Sharma et al. 1991). Hepatotoxicity can be generated by certain common causes including therapeutic agents, natural chemicals, laboratory and manufacturing agents and herbal therapies (Ostapowicz et al. 2002).

Carbon tetra chloride (CCl_4) is one of the most communal models for inducing hepatotoxicity. It is transformed into a toxic $\text{CCl}_3^\cdot$ radical by hepatic cytochrome P4502E1 (CYP2E1). Thus; it brings an acute Centro-lobular necrosis which starts a wound healing response (fibrosis) (Domenicali et al. 2009). However, Contact to these chemicals in humans is rare and generally occurs in the manufacturing during fabrication and in places where these chemicals is usually used (Mormone et al. 2011).

Transforming growth factor β receptors (TGF- β Rs) are of 2 types TGF- β RI and TGF- β RII. They mediate hepatic stellate cell (HSC) activation (Roberts 1999) after binding to their ligand cytokine TGF β , the profibrogenic cytokine that traditionally have been considered the key fibrogenic stimulus to HSC (Tsukamoto 1999).

Fibroblast growth factor receptor 3 (FGFR3) is involved in cell growth control, cell differentiation, and migration (Kanai et al. 1997). There are many reports that indicated the involvement of FGF/ FGF receptor (FGFR) signaling in the progression liver diseases including fibrosis (Bataller and Brenner 2005; Gressner and Weiskirchen 2006) and hepatocellular carcinoma (Amann et al. 2010; Harimoto et al. 2010; Ho et al. 2009; Huang et al. 2009).

The aim of this study was to investigate the expression pattern of TGF β RI and FGFR3 at different stages of liver injury. This aspect of study was verified by investigation of the localization of these proteins in different liver injury stages.

2. METHODOLOGY

2.1. Animal model.

Adult male Sprague-Dawley rats weighing 250–300 g and aging 70 days were used for the current study. The animals were obtained from the breeding colony maintained at the animal house of the Nile Company for pharmaceuticals, Cairo, Egypt. They were housed in the animal facility of Faculty of Pharmacy, Al-Azhar University in 20 X 18 X 25 cm plastic cages with stainless steel wire lids and mesh floor with 5 animals per cage. They were kept at $23 \pm 1^\circ \text{C}$, at 55 % relative humidity, with 12:12-h light: dark cycle, and maintained on a standard rodent chow (El-Nasr Company, Abou-Zaabal, Egypt), and allowed to food and water *ad libitum*. Animals were randomly divided into four groups: **control group**: 9 rats: receiving corn oil (2ml/kg/twice weekly/IP) ; **acute toxicity group**: 10 rats were injected 50 % CCl_4 in corn oil (4 ml/kg/IP/single dose) (Fleurentin et al. 1986) ; **6weeks group**: 12 rats were injected with 50% CCl_4 in corn oil (4 ml/kg/IP/twice weekly/6weeks) and finally **11weeks group**: 10 rats were injected with 50 % CCl_4 in corn oil (4 ml/kg/IP/twice weekly/6 weeks) followed by 5 weeks of CCl_4 treatment with the half previous dose. At the end of experimental period; rats were anesthetized with diethyl ether and blood samples were withdrawn from ocular vein for measurement of blood chemistry. The animals then were euthanized, liver tissue samples were harvested and divided into 2 parts; the first was processed by standard histology and immunofluorescence techniques and the other was homogenized in 0.15 M KCl for MDA and SOD assay. All animal procedures were performed in accordance with the international guide for the care and use of laboratory animals (Institute of Laboratory Animal Resources (US) et al. 1985)

2.2. Antibodies and chemicals.

Rabbit polyclonal TGF β RI and FGFR3 antibodies were purchased from Santa Cruz Biotechnology (CA, USA). Cy3-conjugated goat anti-rabbit antibody was purchased from Jackson ImmunoResearch (PA, USA). 4,6- Diamidino-2- phenyl indol (DAPI). CCl_4 was purchased from Sigma-Aldrich (MO, USA).

2.3. Biochemical analysis.

Serum enzymatic activities of transaminases (ALT and AST) were estimated by kinetic method according to the method of international federation of clinical chemistry (IFCC) (Bergmeyer et al. 1986a; Bergmeyer et al. 1986b). Alkaline phosphatase (ALP) activity was assay according to the method of IFCC (Tietz et al. 1983a; Tietz et al. 1983b; Tietz et al. 1983c) and serum albumin concentration according to the method described by Gendler (Gendler 1984). The liver homogenate was used for the determination of the oxidative stress parameters. The level of thiobarbituric acid-reactive substances (measured as malondialdehyde (MDA) was determined as described by Mihara

and Uchiyama (Mihara and Uchiyama 1978). The activity of SOD was determined using the method described by Marklund (Marklund 1985).

2.4. Immunofluorescence analysis.

Slides containing liver tissue sections were handled according to the method described by Abdel-Bakky and his associates (Abdel-Bakky et al. 2011). The primary TGF β R1 and FGFR3 antibodies were diluted in blocking solution in the suitable dilution (1:400) and left overnight in 4 °C. Secondary antibody (cyanine red conjugated) diluted in the blocking solution was incubated for 30 min and the nuclei were counterstained using DAPI. Finally, all slides were mounted with the fluoromount solution, covered by covering slips, and allowed to stand for detection by immunofluorescence microscope (Leica DM 5500B).

2.5. Statistical analysis.

Data were presented as the mean $\pm$ standard error of mean (M $\pm$ SEM). Statistical analysis was performed using one-way analysis of variance (ANOVA) followed by Tukey-Kramer as a post test, according to the number of groups. The 0.05 level of probability was used as the criterion of significance using GraphPad Prism software version 5 (GraphPad Software Inc, CA, USA).

3. RESULTS

3.1. LIVER FUNCTIONS AND OXIDATIVE STATUS ASSESSMENT.

To assess liver functions; we have performed liver function tests including serum transaminases, ALP, and albumin. The oxidative status of liver tissues was determined through MDA and SOD assay as indicated in was shown to significantly decrease in CCl₄ treated groups compared to control group.

Table 1.

Administration of I.P. CCl₄ significantly elevated serum transaminases activities compared to control group whatever the duration of administration. On the other hand; ALP showed significant elevation only in chronic administration of CCl₄ with minimal change in single dose CCl₄ treatment. Supporting previous results; albumin showed significant decrease only with 11 weeks CCl₄ treatment.

Regarding thiobarbituric reactive species assessment observed in was shown to significantly decrease in CCl₄ treated groups compared to control group.

Table 1; the tissue MDA content was significantly increased on CCl₄ treated groups compared to control group. On the other hand; the antioxidant SOD was shown to significantly decrease in CCl₄ treated groups compared to control group.

Table 1: Liver functions and oxidative status assessment tests.

	<i>ALT(IU/L)</i>	<i>AST(IU/L)</i>	<i>ALP(IU/L)</i>	<i>Albumin(g/dl)</i>	<i>MDA(nmol/g tissue)</i>	<i>SOD(U/mg tissue)</i>
Control	46.6 $\pm$ 2.85	54.1 $\pm$ 2.65	312 $\pm$ 21.9	3.81 $\pm$ 0.08	4.73 $\pm$ 0.318	526 $\pm$ 25.2
CCl₄ single I.P. dose	294 $\pm$ 11.9 ^{(a)(b)}	419 $\pm$ 11.0 ^(a)	395 $\pm$ 11.1 ^(b)	3.8 $\pm$ 0.06 ^(b)	23.7 $\pm$ 2.35 ^{(a)(b)}	308 $\pm$ 8.05 ^{(a)(b)}
CCl₄ 6 weeks I.P.	349 $\pm$ 13.4 ^(a)	436 $\pm$ 15.4 ^(a)	570 $\pm$ 24.5 ^(a)	3.39 $\pm$ 0.13	31.9 $\pm$ 1.44 ^(a)	223 $\pm$ 14 ^(a)

CCl ₄	11	298±8.48 ^(a)	368±13.4 ^{(a)(b)}	790±24.9 ^{(a)(b)}	2.69±0.07 ^(a)	38.1±1.74 ^(a)	171±6.57 ^(a)
weeks I.P.							

Data are expressed as mean ± SEM

(a) Significantly different from control group

(b) Significantly different from 6 weeks CCl₄ group using one-way ANOVA followed by Tukey-Kramer test for multiple comparison test at P≤0.05

3.2. EXPRESSION AND LOCALIZATION OF TGFBR1.

Figure 1 shows that TGFβR1 protein showed minimal expression liver tissues of control group animals and also animals treated with single CCl₄ dose as a model of acute toxicity. The expression was increased on conversion of toxicity from acute to chronic with maximal expression in 6 and 11 weeks groups. As indicated in **Graph 1** ; it was noted that the expression increased by about 146% in 6 weeks CCl₄ treatment group and by 55 % in 11 weeks CCl₄ treatment group. Regarding localization; it was observed that the expression is located in the cell membrane of epithelial hepatic tissue. It was also noted that the expression occurred in areas that shows maximal lesions as necrosis and steatosis. On the other hand; it appears as intense area filling the cytoplasm extending along the fibrous septa and surrounding the cirrhotic nodule in areas that show high density of fibroblastic cells as shown in 11 weeks group. On the other hand there was also minimal expression inside the cirrhotic nodule.





Figure 1: Effect of CCl₄ administration on hepatic expression of TGFβR1 protein
Immunofluorescence staining of liver sections of CCl₄ treated rats showing minimal TGFβR1 expression in control group and also in single I.P. treated group. Six weeks CCl₄ treated group

showed maximal expression located mainly in cell membrane (yellow rectangle).Eleven weeks treatment showed constitutive expression (yellow rectangle) occurred mainly at area of fibrous septa or nodule border (white arrows) with minimal expression in cirrhotic nodule (blue arrows).



Graph 1: Effect of CCl₄ administration on hepatic expression of TGFβR1 protein

Fluorescence intensity was obtained from 5 fields of each section (minimally 2 rats of each group) using ImageJ software.

Data are expressed as mean ± SEM

(a) Significantly different from control group

(b) Significantly different from 6 weeks CCl₄ group one-way ANOVA followed by Tukey-Kramer test for multiple comparison test at P≤0.05

3.3. EXPRESSION AND LOCALIZATION OF FGFR3.

Figure 2 and Graph 2 show that FGFR3 protein shows minimal expression in liver tissues of control group animals and also animals treated with single CCl₄ dose as a model of acute toxicity. The expression was increased on conversion of toxicity from acute to chronic with maximal expression in 6 and 11 weeks groups. It was observed that FGFR3 expression occurs in the cytoplasm of the cells that found in the affected areas as areas of steatosis, underlying fibrosis and fibrous septa. It was noted that the expression increased by about 146% in 6 weeks CCl₄ treatment group and. Intraperitoneal administration of CCl₄ for 11 weeks resulted in maximal expression that increased by about 222% compared to control.





Figure 2: Effect of CCl₄ administration on hepatic expression and localization of FGFR3 in CCl₄ treated rats.

Fluorescence intensity was obtained from 5 fields of each section (minimally 2 rats of each group) using ImageJ software.

Data are expressed as mean $\pm$ SEM

(a) Significantly different from control group

(b) Significantly different from 6 weeks CCl₄ group one-way ANOVA followed by Tukey-Kramer test for multiple comparison test at $P \leq 0.05$



Graph 2: Effect of CCl₄ administration on hepatic expression and localization of FGFR3 protein

Data are analysed using one-way ANOVA followed by Turkey-Kramer test for multiple comparison at $P \leq 0.05$.

- (a) Significantly different from control.
- (b) Significantly different from 6 weeks CCl₄ group.

Fluorescence intensity was obtained from 5 fields of each section (minimally 2 rats of each group) using ImageJ software.

3.4. HISTOPATHOLOGICAL FINDINGS

Effects of CCl₄ treatment on histopathological findings of liver tissue are represented in

Table 2 and **Figure 3**. The control group showed normal hepatic architecture. On contrast, CCl₄ treated groups showed pathological findings changes differed with the duration of treatment.

Single I.P. dose treated group showed average portal tract without interface activity or underlying fibrosis. On the other hand; it showed spotty necrosis, and mild micro-vesicular steatosis and dilated central vein. Six weeks treatment caused expanded portal tract with fibrous septa extending from a portal tract to another, marked micro- and macro-vesicular steatosis. The hepatocytes exhibited some aspects of single cell necrosis with dilated central veins and mild interface activity.

Eleven weeks treatment showed markedly expanded portal tract with definite inflammatory infiltrate, complete nodular formation (definite cirrhosis) and marked micro- and macro-vesicular steatosis. The hepatocytes exhibited single cell necrosis with mild spotty necrosis. Finally; the central veins were markedly dilated with marked interface activity.

Table 2: Histopathological findings of the studied groups

	control	Single I.P. CCl ₄	CCl ₄ 6 weeks	CCl ₄ 11 weeks
CV	0	+	+	++
Steatosis	0	+	+++	+++
Hepatocyte	0	++	+	+
Spotty necrosis	0	++	0	+
Interface activity	0	0	+	++
PT	0	0	+	++
Fibrosis	0	0	++	++++

Central vein (CV):

0: within normal +: dilated ++: markedly dilated

Steatosis, Spotty necrosis, Interface activity:

0: no +: mild ++: moderate to marked

Hepatocytes:

0: within normal +: single cell necrosis ++: confluent or diffuse necrosis

Portal tract (PT):

0: within normal +: expanded ++: expanded with inflammatory infiltrate

Fibrosis:

0: no fibrosis

+: fibrosis confined to enlarged portal zones

++: fibrosis of peri-portal or portal-portal septa with intact architecture

+++ : architectural distortion (septal or bridging fibrosis) without obvious cirrhosis

++++: probable or definite cirrhosis




Figure 3: Histopathological micrograph of liver samples of CCl₄ treated groups $\times 235$ using H and E stain. **Control:** liver tissue showing average **portal tract** (yellow arrows), average central vein (red arrow), and average hepatocytes arranged in cords. **Single I.P. CCl₄ dose:** liver tissue showing average **portal tract** (yellow arrow), spotty necrosis (black arrow), and mild micro-vesicular steatosis. **6 weeks I.P. CCl₄:** liver tissue showing expanded **portal tract** with underlying fibrosis and fibrous septa extending **from a portal tract to another** (yellow arrows), marked micro- and macro-vesicular steatosis. **11 weeks I.P. CCl₄:** liver tissue showing markedly expanded **portal tract** (yellow arrows), complete nodular formation, marked micro- and macro-vesicular steatosis.

4. DISCUSSION

Administration of CCl₄ either a single I.P. dose or chronic I.P. doses for 6 or 11 weeks significantly elevated serum transaminases enzymes activities suggesting hepatocellular damage. These results agreed with previous reports that indicated that CCl₄ significantly increases serum transaminases (Ahsan et al. 2009; Dalton et al. 2009b; Kalu et al. 2011a). This CCl₄ induced hepatic damage was reported to be due to oxidative stress (Manibusan et al. 2007; Weber et al. 2003). **This hepatocellular damage was supported to some extent by serum ALP activity that showed non-significant increase after single I.P. CCl₄ treatment compared to control group** suggesting minimal biliary injury detected upon that model.

This result opposes what was reported by Kālu's team (Kalu, Ogugua, Ujowundu, & Nwaoguikpe 2011a). This difference might be due difference in animal strain or route of administration that has not been mentioned. On the other hand; ALP elevation in chronic models including 6 weeks, 11 weeks groups showed significant increase compared to control which is less than 3 times as control; a result that might suggest hepatotoxicity and mild biliary toxicity. This matches with that previously reported by Posen and Doherty (Posen and Doherty 1981). Continuous CCl₄ for 11 weeks showed significant elevation in ALP activity compared to 6 weeks CCl₄ treatment suggesting that **chronic hepatocellular intoxication might lead to biliary injury. Supporting previous data; Serum albumin concentration showed only significant decrease from control at 11 weeks CCl₄ treatment, a group that showed cirrhotic nodule formation suggesting decreased functioning tissue mass as reported by Giannini and his team (Giannini et al. 2005).**

Meanwhile; it was clarified that free radicals production and oxidative stress are main players in liver injury especially CCl₄ induced liver injury (Dalton et al. 2009a; Kalu et al. 2011b; Manibusan, Odin, & Eastmond 2007; Noori et al. 2009; Weber, Boll, & Stampfl 2003); reports that agreed with our results that showed that administration of CCl₄ significantly elevated tissue content of MDA and reduced serum SOD activity.

Supporting the measured biochemical data: Our findings demonstrated that single I.P. dose of CCl₄ resulted in marked spotty necrosis and confluent hepatocytes necrosis. On the other hand prolonged administration of CCl₄ to 6 weeks produced fibrosis with intact architecture while prolonged CCl₄ to 11 weeks produced definite cirrhosis with clear cirrhotic nodule. This agreed with what has been reported that histopathological changes occur according to CCl₄ administration period. A single dose of CCl₄ leads to centrilobular necrosis and steatosis (Pierce et al. 1987), while continued administration leads to hepatic fibrosis, cirrhosis, and HCC (Tamayo 1983)

The TGF- β is the principal regulator in chronic liver injury sharing in all stages of disease progression (Dooley and ten 2012). Its action begins by binding to its receptor TGF β RI and TGF β RII (Devaux et al. 2011a). It was observed that TGF β RI expression occurs intracellularly in the cell membrane. This agrees with Massague and Chen reports (Massague and Chen 2000). It was also shown that TGF β RI expression was only upregulated in chronic liver toxicity; specifically phases that showed some extent of tissue remodeling prescribed by Devaux and his team (Devaux et al. 2011b) suggesting involvement of TGF β RI in cellular processes involved in chronic not acute liver injury. This was similar to the previous reports in myocardial infarction (MI) by Devaux and his team (Devaux, Bousquenaud, Rodius, Marie, Maskali, Zhang, Azuaje, & Wagner 2011b). Besides; they also showed that the maximal expression occurs in lesion areas suggesting the direct relationship between TGF β RI expression and lesions grade; a result that also is quite similar to Devaux and his team reports (Devaux, Bousquenaud, Rodius, Marie, Maskali, Zhang, Azuaje, & Wagner 2011b).

The FGF/FGFR signaling axis has been reported to be a contributor to fibrosis in the liver (Bataller & Brenner 2005; Gressner & Weiskirchen 2006). On the other hand FGFR3 was reported to be activated by FGF2 (Ornitz and Leder 1992); a cytokine that has been believed to be involved in fibrotic disorders (Masamune et al. 2005; Prasse et al. 2006)

Our results showed that FGFR3 expression increased in chronically intoxicated groups suggesting involvement of FGFR3 in chronic liver injury processes. A result that is quite similar to reports of Lee's team (Lee et al. 2015). Lee and his team have also reported that expression of all FGFR seem to be cytoplasmic. This is quite similar to our results. Our results showed that the expression of FGFR3 appeared as large spread spot that may indicate that the expression was cytoplasmic.

5. CONCLUSION

In conclusion, our findings indicate, for the first time, that TGF β RI and FGFR3 are upregulated in chronic not acute liver injury. TGF β RI is upregulated in injury combined with underlying fibrosis or cirrhosis while FGFR3 is upregulated in injury combined with steatosis, fibrosis and cirrhosis; results that may suggest usage of TGF β RI and FGFR3 as a candidate markers for diagnosis and prognosis of chronic liver diseases and a target for liver disease therapy.

REFERENCES

REFERENCES

ABDEL-BAKKY, M.S., HAMMAD, M.A., WALKER, L.A., & ASHFAQ, M.K. 2011. TISSUE FACTOR DEPENDENT LIVER INJURY CAUSES RELEASE OF RETINOID RECEPTORS (RXR-ALPHA AND RAR-ALPHA) AS LIPID DROPLETS. *BIOCHEM.BIOPHYS.RES.COMMUN.*, 410, (1) 146-151 AVAILABLE FROM: PM:21658367

AHSAN, R., ISLAM, K.M., MUSADDIK, A., & HAQUE, E. 2009. HEPATOPROTECTIVE ACTIVITY OF METHANOL EXTRACT OF SOME MEDICINAL PLANTS AGAINST CARBON TETRACHLORIDE INDUCED HEPATOTOXICITY IN ALBINO RATS. *GLOBAL J PHARMACOL*, 3, (3) 116-122

AMANN, T., BATAILLE, F., SPRUSS, T., DETTMER, K., WILD, P., LIEDTKE, C., MUHLBAUER, M., KIEFER, P., OEFNER, P.J., TRAUTWEIN, C., BOSSERHOFF, A.K., & HELLERBRAND, C. 2010. REDUCED EXPRESSION OF FIBROBLAST GROWTH FACTOR RECEPTOR 2IIIB IN HEPATOCELLULAR CARCINOMA INDUCES A MORE AGGRESSIVE GROWTH. *AM.J.PATHOL.*, 176, (3) 1433-1442 AVAILABLE FROM: PM:20093481

BATALLER, R. & BRENNER, D.A. 2005. LIVER FIBROSIS. *J.CLIN.INVEST*, 115, (2) 209-218 AVAILABLE FROM: PM:15690074

BERGMEYER, H.U., HORDER, M., & REJ, R. 1986A. INTERNATIONAL FEDERATION OF CLINICAL CHEMISTRY (IFCC) SCIENTIFIC COMMITTEE, ANALYTICAL SECTION: APPROVED RECOMMENDATION (1985) ON IFCC METHODS FOR THE MEASUREMENT OF CATALYTIC CONCENTRATION OF ENZYMES. PART 2. IFCC METHOD FOR ASPARTATE AMINOTRANSFERASE (L-ASPARTATE: 2-OXOGLUTARATE AMINOTRANSFERASE, EC 2.6.1.1). *J.CLIN.CHEM.CLIN.BIOCHEM.*, 24, (7) 497-510 AVAILABLE FROM: PM:3734712

BERGMEYER, H.U., HORDER, M., & REJ, R. 1986B. INTERNATIONAL FEDERATION OF CLINICAL CHEMISTRY (IFCC) SCIENTIFIC COMMITTEE, ANALYTICAL SECTION: APPROVED RECOMMENDATION (1985) ON IFCC METHODS FOR THE MEASUREMENT OF CATALYTIC CONCENTRATION OF ENZYMES. PART 3. IFCC METHOD FOR ALANINE AMINOTRANSFERASE (L-ALANINE: 2-OXOGLUTARATE AMINOTRANSFERASE, EC 2.6.1.2). *J.CLIN.CHEM.CLIN.BIOCHEM.*, 24, (7) 481-495 AVAILABLE FROM: PM:3734711

DALTON, S.R., LEE, S.M., KING, R.N., NANJI, A.A., KHARBANDA, K.K., CASEY, C.A., & MCVICKER, B.L. 2009A. CARBON TETRACHLORIDE-INDUCED LIVER DAMAGE IN ASIALOGLYCOPROTEIN RECEPTOR-DEFICIENT MICE. *BIOCHEM.PHARMACOL.*, 77, (7) 1283-1290 AVAILABLE FROM: PM:19185565

DALTON, S.R., LEE, S.M., KING, R.N., NANJI, A.A., KHARBANDA, K.K., CASEY, C.A., & MCVICKER, B.L. 2009B. CARBON TETRACHLORIDE-INDUCED LIVER DAMAGE IN ASIALOGLYCOPROTEIN RECEPTOR-DEFICIENT MICE. *BIOCHEMICAL PHARMACOLOGY*, 77, (7) 1283-1290

DEVAUX, Y., BOUSQUENAUD, M., RODIUS, S., MARIE, P.Y., MASKALI, F., ZHANG, L., AZUAJE, F., & WAGNER, D.R. 2011A. TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1 IS A NEW CANDIDATE PROGNOSTIC BIOMARKER AFTER ACUTE

MYOCARDIAL INFARCTION. *BMC.MED.GENOMICS*, 4, 83 AVAILABLE FROM: PM:22136666

DEVAUX, Y., BOUSQUENAUD, M., RODIUS, S., MARIE, P.Y., MASKALI, F., ZHANG, L., AZUAJE, F., & WAGNER, D.R. 2011B. TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1 IS A NEW CANDIDATE PROGNOSTIC BIOMARKER AFTER ACUTE MYOCARDIAL INFARCTION. *BMC.MED.GENOMICS*, 4, 83 AVAILABLE FROM: PM:22136666

DOMENICALI, M., CARACENI, P., GIANNONE, F., BALDASSARRE, M., LUCCHETTI, G., QUARTA, C., PATTI, C., CATANI, L., NANNI, C., LEMOLI, R.M., & BERNARDI, M. 2009. A NOVEL MODEL OF CCL4-INDUCED CIRRHOSIS WITH ASCITES IN THE MOUSE. *J.HEPATOL.*, 51, (6) 991-999 AVAILABLE FROM: PM:19853952

DOOLEY, S. & TEN, D.P. 2012. TGF-BETA IN PROGRESSION OF LIVER DISEASE. *CELL TISSUE RES.*, 347, (1) 245-256 AVAILABLE FROM: PM:22006249

FLEURENTIN, J., HOEFLER, C., LEXA, A., MORTIER, F., & PELT, J.M. 1986. HEPATOPROTECTIVE PROPERTIES OF CREPIS RUEPPELLII AND ANISOTES TRISULCUS: TWO TRADITIONAL MEDICINAL PLANTS OF YEMEN. *J.ETHNOPHARMACOL.*, 16, (1) 105-111 AVAILABLE FROM: PM:3747559

GENDLER, S. 1984. URIC ACID. KAPLAN A ET AL. *CLIN CHEM THE CV MOSBY CO.ST LOUIS.TORONTO.PRINCETON* 1268-1273

GIANNINI, E.G., TESTA, R., & SAVARINO, V. 2005. LIVER ENZYME ALTERATION: A GUIDE FOR CLINICIANS. *CANADIAN MEDICAL ASSOCIATION JOURNAL*, 172, (3) 367-379

GRESSNER, A.M. & WEISKIRCHEN, R. 2006. MODERN PATHOGENETIC CONCEPTS OF LIVER FIBROSIS SUGGEST STELLATE CELLS AND TGF-BETA AS MAJOR PLAYERS AND THERAPEUTIC TARGETS. *J.CELL MOL.MED.*, 10, (1) 76-99 AVAILABLE FROM: PM:16563223

HARIMOTO, N., TAGUCHI, K., SHIRABE, K., ADACHI, E., SAKAGUCHI, Y., TOH, Y., OKAMURA, T., KAYASHIMA, H., TAKETOMI, A., & MAEHARA, Y. 2010. THE SIGNIFICANCE OF FIBROBLAST GROWTH FACTOR RECEPTOR 2 EXPRESSION IN DIFFERENTIATION OF HEPATOCELLULAR CARCINOMA. *ONCOLOGY*, 78, (5-6) 361-368 AVAILABLE FROM: PM:20798558

HO, H.K., POK, S., STREIT, S., RUHE, J.E., HART, S., LIM, K.S., LOO, H.L., AUNG, M.O., LIM, S.G., & ULLRICH, A. 2009. FIBROBLAST GROWTH FACTOR RECEPTOR 4 REGULATES PROLIFERATION, ANTI-APOPTOSIS AND ALPHA-FETOPROTEIN SECRETION DURING HEPATOCELLULAR CARCINOMA PROGRESSION AND REPRESENTS A POTENTIAL TARGET FOR THERAPEUTIC INTERVENTION. *J.HEPATOL.*, 50, (1) 118-127 AVAILABLE FROM: PM:19008009

HUANG, X., YANG, C., JIN, C., LUO, Y., WANG, F., & MCKEEHAN, W.L. 2009. RESIDENT HEPATOCYTE FIBROBLAST GROWTH FACTOR RECEPTOR 4 LIMITS HEPATOCARCINOGENESIS. *MOL.CARCINOGEN.*, 48, (6) 553-562 AVAILABLE FROM: PM:19009564

INSTITUTE OF LABORATORY ANIMAL RESOURCES (US), USE OF LABORATORY ANIMALS, & NATIONAL INSTITUTES OF HEALTH (US) 1985. *GUIDE FOR THE CARE AND USE OF LABORATORY ANIMALS* NATIONAL ACADEMIES.

KALU, F.N., OGUGUA, V.N., UJOWUNDU, C.O., & NWAOGUIKPE, R.N. 2011A. AQUEOUS EXTRACT OF COMBRETUM DOLICHOPENTALUM LEAF-A POTENT INHIBITOR OF CARBON TETRACHLORIDE INDUCED HEPATOTOXICITY IN RATS. *JOURNAL OF APPLIED PHARMACEUTICAL SCIENCE*, 1, (10) 114

KALU, F.N., OGUGUA, V.N., UJOWUNDU, C.O., & NWAOGUIKPE, R.N. 2011B. AQUEOUS EXTRACT OF COMBRETUM DOLICHOPENTALUM LEAF-A POTENT INHIBITOR OF CARBON TETRACHLORIDE INDUCED HEPATOTOXICITY IN RATS.

KANAI, M., GOKE, M., TSUNEKAWA, S., & PODOLSKY, D.K. 1997. SIGNAL TRANSDUCTION PATHWAY OF HUMAN FIBROBLAST GROWTH FACTOR RECEPTOR 3. IDENTIFICATION OF A NOVEL 66-KDA PHOSPHOPROTEIN. *J.BIOL.CHEM.*, 272, (10) 6621-6628 AVAILABLE FROM: PM:9045692

LEE, H.J., KANG, H.J., KIM, K.M., YU, E.S., KIM, K.H., KIM, S.M., KIM, T.W., SHIM, J.H., LIM, Y.S., LEE, H.C., CHUNG, Y.H., & LEE, Y.S. 2015. FIBROBLAST GROWTH FACTOR RECEPTOR ISOTYPE EXPRESSION AND ITS ASSOCIATION WITH OVERALL SURVIVAL IN PATIENTS WITH HEPATOCELLULAR CARCINOMA. *CLIN.MOL.HEPATOL.*, 21, (1) 60-70 AVAILABLE FROM: PM:25834803

MANIBUSAN, M.K., ODIN, M., & EASTMOND, D.A. 2007. POSTULATED CARBON TETRACHLORIDE MODE OF ACTION: A REVIEW. *J.ENVIRON.SCI.HEALTH C.ENVIRON.CARCINOGENECOTOXICOL.REV.*, 25, (3) 185-209 AVAILABLE FROM: PM:17763046

MARKLUND, S.L. 1985. SUPEROXIDE DISMUTASE ISOENZYMES IN TISSUES AND PLASMA FROM NEW ZEALAND BLACK MICE, NUDE MICE AND NORMAL BALB/C MICE. *MUTAT.RES.*, 148, (1-2) 129-134 AVAILABLE FROM: PM:3969077

MASAMUNE, A., SATOH, M., KIKUTA, K., SUZUKI, N., & SHIMOSEGAWA, T. 2005. ENDOTHELIN-1 STIMULATES CONTRACTION AND MIGRATION OF RAT PANCREATIC STELLATE CELLS. *WORLD J.GASTROENTEROL.*, 11, (39) 6144-6151 AVAILABLE FROM: PM:16273641

MASSAGUE, J. & CHEN, Y.G. 2000. CONTROLLING TGF-BETA SIGNALING. *GENES DEV.*, 14, (6) 627-644 AVAILABLE FROM: PM:10733523

MIHARA, M. & UCHIYAMA, M. 1978. DETERMINATION OF MALONALDEHYDE PRECURSOR IN TISSUES BY THIOBARBITURIC ACID TEST. *ANAL.BIOCHEM.*, 86, (1) 271-278 AVAILABLE FROM: PM:655387

MORMONE, E., GEORGE, J., & NIETO, N. 2011. MOLECULAR PATHOGENESIS OF HEPATIC FIBROSIS AND CURRENT THERAPEUTIC APPROACHES. *CHEM.BIOL.INTERACT.*, 193, (3) 225-231 AVAILABLE FROM: PM:21803030

NOORI, S., REHMAN, N., QURESHI, M., & MAHBOOB, T. 2009. REDUCTION OF CARBON TETRACHLORIDE-INDUCED RAT LIVER INJURY BY COFFEE AND GREEN TEA. *PAKISTAN JOURNAL OF NUTRITION*, 8, (4) 452-458

ORNITZ, D.M. & LEDER, P. 1992. LIGAND SPECIFICITY AND HEPARIN DEPENDENCE OF FIBROBLAST GROWTH FACTOR RECEPTORS 1 AND 3. *J.BIOL.CHEM.*, 267, (23) 16305-16311 AVAILABLE FROM: PM:1379594

OSTAPOWICZ, G., FONTANA, R.J., SCHIODT, F.V., LARSON, A., DAVERN, T.J., HAN, S.H., MCCASHLAND, T.M., SHAKIL, A.O., HAY, J.E., HYNAN, L., CRIPPIN, J.S., BLEI,

A.T., SAMUEL, G., REISCH, J., & LEE, W.M. 2002. RESULTS OF A PROSPECTIVE STUDY OF ACUTE LIVER FAILURE AT 17 TERTIARY CARE CENTERS IN THE UNITED STATES. *ANN.INTERN.MED.*, 137, (12) 947-954 AVAILABLE FROM: PM:12484709

PIERCE, R.A., GLAUG, M.R., GRECO, R.S., MACKENZIE, J.W., BOYD, C.D., & DEAK, S.B. 1987. INCREASED PROCOLLAGEN MRNA LEVELS IN CARBON TETRACHLORIDE-INDUCED LIVER FIBROSIS IN RATS. *J.BIOL.CHEM.*, 262, (4) 1652-1658 AVAILABLE FROM: PM:3805048

POSEN, S. & DOHERTY, E. 1981. THE MEASUREMENT OF SERUM ALKALINE PHOSPHATASE IN CLINICAL MEDICINE. *ADV.CLIN.CHEM.*, 22, 163-245 AVAILABLE FROM: PM:7027760

PRASSE, A., PECHKOVSKY, D.V., TOEWS, G.B., JUNGRAITHMAYR, W., KOLLERT, F., GOLDMANN, T., VOLLMER, E., MULLER-QUERNHEIM, J., & ZISSEL, G. 2006. A VICIOUS CIRCLE OF ALVEOLAR MACROPHAGES AND FIBROBLASTS PERPETUATES PULMONARY FIBROSIS VIA CCL18. *AM.J.RESPIR.CRIT CARE MED.*, 173, (7) 781-792 AVAILABLE FROM: PM:16415274

ROBERTS, A.B. 1999. TGF-BETA SIGNALING FROM RECEPTORS TO THE NUCLEUS. *MICROBES.INFECT.*, 1, (15) 1265-1273 AVAILABLE FROM: PM:10611754

SHARMA, A., CHAKRABORTI, K.K., & HANDA, S.S. 1991. ANTIHEPATOTOXIC ACTIVITY OF SOME INDIAN HERBAL FORMULATIONS AS COMPARED TO SILYMARIN. *FITOTERAPIA*, 62, 229-235

TAMAYO, R.P. 1983. IS CIRRHOSIS OF THE LIVER EXPERIMENTALLY PRODUCED BY CC14 AN ADEQUATE MODEL OF HUMAN CIRRHOSIS? *HEPATOLOGY*, 3, (1) 112-120

TIETZ, N.W., BURTIS, C.A., DUNCAN, P., ERVIN, K., PETITCLERC, C.J., RINKER, A.D., SHUEY, D., & ZYGOWICZ, E.R. 1983A. A REFERENCE METHOD FOR MEASUREMENT OF ALKALINE PHOSPHATASE ACTIVITY IN HUMAN SERUM. *CLIN.CHEM.*, 29, (5) 751-761 AVAILABLE FROM: PM:6404566

TIETZ, N.W., RINKER, A.D., & SHAW, L.M. 1983B. IFCC METHODS FOR THE MEASUREMENT OF CATALYTIC CONCENTRATION OF ENZYMES PART 5. IFCC METHOD FOR ALKALINE PHOSPHATASE (ORTHOPHOSPHORIC-MONOESTER PHOSPHOHYDROLASE, ALKALINE OPTIMUM, EC 3.1.3.1). *J.CLIN.CHEM.CLIN.BIOCHEM.*, 21, (11) 731-748 AVAILABLE FROM: PM:6655448

TIETZ, N.W., RINKER, A.D., & SHAW, L.M. 1983C. INTERNATIONAL FEDERATION OF CLINICAL CHEMISTRY. IFCC METHODS FOR THE MEASUREMENT OF CATALYTIC CONCENTRATION OF ENZYMES. PART 5. IFCC METHOD FOR ALKALINE PHOSPHATASE (ORTHOPHOSPHORIC-MONOESTER PHOSPHOHYDROLASE, ALKALINE OPTIMUM, EC 3.1.3.1). IFCC DOCUMENT STAGE 2, DRAFT 1, 1983-03 WITH A VIEW TO AN IFCC RECOMMENDATION. *CLIN.CHIM.ACTA*, 135, (3) 339F-367F AVAILABLE FROM: PM:6661822

TSUKAMOTO, H. 1999. CYTOKINE REGULATION OF HEPATIC STELLATE CELLS IN LIVER FIBROSIS. *ALCOHOL CLIN.EXP.RES.*, 23, (5) 911-916 AVAILABLE FROM: PM:10371413

WEBER, L.W., BOLL, M., & STAMPFL, A. 2003. HEPATOTOXICITY AND MECHANISM OF ACTION OF HALOALKANES: CARBON TETRACHLORIDE AS A TOXICOLOGICAL MODEL. *CRIT REV.TOXICOL.*, 33, (2) 105-136 AVAILABLE FROM: PM:12708612

